Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019, before the market opens.
The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.
About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...
